In vivo, these PTEN mutations cause more rapid tumor formation and progression than that observed in mice with PTEN heterozygous condition (PTEN+/− mice) [96,99], suggesting that patients harboring these PTEN alterations may display heightened sensitivity to therapies directed at PI3K and/or AKT inhibition. This evidence concerns the gene PIK3CA and neoplasm.